Profile: Alere Inc (ALR.N)
21 Oct 2016
Alere Inc., incorporated on May 11, 2001, is a provider of health information through diagnostic tests. The Company's segments include professional diagnostics, consumer diagnostics, and corporate and other. The professional diagnostics segment includes an array of diagnostic test products and other in vitro diagnostic tests marketed to medical professionals and laboratories for detection of diseases and conditions within its areas of focus. The consumer diagnostics segment consists primarily of manufacturing operations related to its role as the exclusive manufacturer of products for SPD Swiss Precision Diagnostics (SPD), its joint venture with The Procter & Gamble Company (P&G).
The Company's professional diagnostic solutions allow patients and their healthcare providers to work together to manage patients' conditions over the continuum of care, from the hospital to home. Professional diagnostics solutions are designed to assist medical professionals in both preventative and interventional medicine, and include testing and monitoring performed in hospitals, laboratories and doctors' offices and patient self-testing, which it defines as testing or monitoring performed at home under the supervision of a medical professional. Professional diagnostic products provide for qualitative or quantitative analysis of patient samples for evidence of a specific medical condition, disease state or toxicological state or to measure response to therapy. Within professional diagnostics, the Company focuses on point-of-care, diagnostic testing and the patient self-testing and patient self-management markets. The point-of-care market for diagnostic products includes all areas where a patient is assessed or diagnosed, including hospitals, laboratories, physician offices, specialized mobile clinics, emergency rooms, rapid-response laboratories and patient health screening locations.
The Company's professional diagnostic products include point-of-care and laboratory tests within the infectious disease, cardiometabolic disease and toxicology markets, as well as patient self-testing services. Its infectious disease diagnostic products are designed to detect certain diseases or groups of diseases and allow medical professionals to make informed health decisions. Disease areas covered include viral hepatitis, respiratory syncytial virus (RSV), influenza, streptococcus, pneumonia, tuberculosis, human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS), gastrointestinal disease, vector-borne diseases such as malaria and dengue, syphilis and other sexually-transmitted diseases. The Company develops and markets a range of point-of-care tests for influenza A & B, RSV, strep A, pneumococcal pneumonia, C. difficile, HIV, hepatitis C (HCV), hepatitis B (HBV), malaria, chlamydia, H. pylori and other infectious diseases. Its tests for infectious disease are sold under brand names that include Alere, Alere i, Alere q, Alere Determine, Acceava, BinaxNOW, Clearview, Panbio, Pima, SD, TECHLAB and Alere TestPack.
The Company's offerings for the diagnosis and management of HIV infection include the Alere Determine HIV-1/2 Ag/Ab Combo, a point-of-care test that detects both HIV-1/2 antibodies and free HIV-1 p24 antigen. In addition to point-of-care products, it offers a line of indirect fluorescent antibody (IFA), assays for over 20 viral, bacterial and autoimmune diseases, a line of serology diagnostic products covering a range of disease categories and over 40 enzyme-linked immunosorbent assay (ELISA), tests for a range of infectious and autoimmune diseases, as well as a line of automated instrumentation for processing ELISA tests.
The Alere Triage System is a diagnostic test system that consists of the Alere Triage MeterPro. This system is designed to aid in the diagnosis, assessment and risk stratification of patients having care issues, including congestive heart failure, acute coronary syndromes, acute myocardial infarction (AMI), and acute kidney injury, and can reduce hospital admissions and improve clinical and economic outcomes. Alere Triage cardiovascular rapid tests include immunoassays for B-type Natriuretic Peptide (BNP), creatine kinase-MB (CK-MB), d-dimer, myoglobin, troponin I and N-terminal pro-Brain Natriuretic Peptide (NT-proBNP). It also offers a version of the Alere Triage BNP Test for use on Beckman Coulter lab analyzers. Its Alere Cholestech LDX System is a portable point-of-care analyzer and test cassette system for testing blood glucose, cholesterol and related lipids. The Alere Cholestech LDX System provides results in over five minutes per test cassette. The Company sells its First Check brand of over-the-counter tests for cholesterol monitoring. It also offers the epoc (enterprise point-of-care) Blood Analysis System for blood gas, electrolyte and metabolite testing. The epoc platform is a point-of-care analysis system which provides wireless bedside blood gas, electrolyte and metabolite measurement testing solutions and complements its Alere Triage products in emergency room and intensive care unit settings.
The Company also offers point-of-care diabetes products, including its Afinion Test System and NycoCard Test System. The Afinion and NycoCard Test Systems are designed to determine the level of glycated hemoglobin (HbA1c), in a patient's blood at the point of care. HbA1c results provide information regarding the patient's average blood sugar levels over a period of time. The NycoCard Test System is a product suited to countries with developing healthcare systems, includes tests for D-Dimer and HbA1c. Through its subsidiary, Arriva Medical, LLC, the Company is a national mail order supplier of diabetic testing supplies, including blood glucose monitors, test strips, lancets, lancing devices, and control solutions, as well as other related medical supplies in the United States. These products are covered by Medicare, Medicaid and other third-party payers. The Company sells disposable, lateral flow diagnostic tests for D-dimer and troponin I under its Clearview brand. Its Alere Home Monitoring business offers patient self-testing services. These services support anticoagulation management through self-testing by patients who take warfarin to control their risk for stroke and clotting disorders.
The Company offers lines of drugs-of-abuse tests, reagent systems and laboratory testing options. Its toxicology business also provides employers with managed drug testing programs. It offers a range of device platforms for the detection of the following illicit and prescription drugs of abuse, including amphetamines/methamphetamines, cocaine, opiates, phencyclidine, tetrahydrocannabinol, acetaminophen, barbiturates, benzodiazepines, methadone, propoxyphene and tricyclic antidepressants, and a range of designer drugs of abuse. In addition, its toxicology products include tests to detect alcohol. Its toxicology tests are sold under the brands, Alere Toxicology, Alere Triage, Alere iCup and SureStep. The Company also offers laboratory-based testing services throughout the United States and in the United Kingdom. The Company provides drug testing services through its eScreen business. It markets and sells consumer drug testing products that test for the presence of prescription drugs, illicit drugs, or both.
The Company competes with Abbott, Becton Dickinson, Meridian Bioscience, Quidel, Danaher, Ortho-Clinical Diagnostics, Siemens, OraSure Technologies, Cepheid, Hologic, INOVA Diagnostics, DiaSorin, Diamedix, Immuno Concepts, Instrumentation Laboratories, Nova Medical, Radiometer, Abaxis Medical Diagnostics, Polymer Technology Systems, mdINR, Bio-Rad Laboratories, Roche Diagnostics, EKF, Samsung, Phamatech, Church & Dwights, Perrigo, Prestige Brands, Walmart, Walgreens and CVS.
51 Sawyer Rd Ste 200
WALTHAM MA 02453-3448
Company Web Links
- CORRECTED-UPDATE 3-Abbott moves ahead on St. Jude, Alere deals, but investors fret
- BRIEF-China clears Abbott's acquisition of Alere
- Abbott moves ahead on St. Jude, Alere deals, but investors fret
- Abbott moves ahead on St. Jude, Alere deals, but investors fret
- BRIEF-FDA concludes Xarelto clinical trial results not affected by Alere's INRatio